Laura Airas
Research
Publications
2024
Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Doerner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Wiendl H, Maurer M, Gimenez-Arnau A, Chitnis T. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204912.Peer-Reviewed Original ResearchSex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals
Laaksonen S, Saraste M, Nylund M, Hinz R, Snellman A, Rinne J, Matilainen M, Airas L. Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals. Frontiers In Neurology 2024, 15: 1352116. PMID: 38445263, PMCID: PMC10913932, DOI: 10.3389/fneur.2024.1352116.Peer-Reviewed Original ResearchDistribution volume ratioNormal-appearing white matterMale MS patientsCortical gray matterMS patientsPositron emission tomographyTSPO bindingMultiple sclerosisDisease progressionHealthy individualsClinical disease progressionWhole-brainBrain positron emission tomographySex differencesMales compared to femalesFemale patientsHealthy womenDisability progressionGreater likelihoodGray matterHealthy controlsStudy cohortFemale controlsEmission tomographyBrainA review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Airas L, Bermel R, Chitnis T, Hartung H, Nakahara J, Stuve O, Williams M, Kieseier B, Wiendl H. A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis. Therapeutic Advances In Neurological Disorders 2024, 17: 17562864241233041. PMID: 38638671, PMCID: PMC11025433, DOI: 10.1177/17562864241233041.Peer-Reviewed Original ResearchBruton tyrosine kinase inhibitorChronic spontaneous urticariaFirst-generation BTK inhibitorSystemic lupus erythematosusBruton's tyrosine kinaseTyrosine kinase inhibitorsMS disease-modifying treatmentsBTK inhibitorsDisease-modifying treatmentsSafety profileB cellsMultiple sclerosisChronic useRheumatoid arthritisSecond-generation BTK inhibitorsB cell depletion therapyTreatment of B-cell malignanciesB-cell modulationDiverse autoimmune conditionsPhase II trialGadolinium-enhancing lesionsB-cell malignanciesMagnetic resonance imaging scansLong-term administrationFemale reproductive health
2023
Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation
Oh J, Airas L, Harrison D, Järvinen E, Livingston T, Lanker S, Malik R, Okuda D, Villoslada P, de Vries H. Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation. Frontiers In Neurology 2023, 14: 1319869. PMID: 38107636, PMCID: PMC10722910, DOI: 10.3389/fneur.2023.1319869.Peer-Reviewed Original ResearchMultiple sclerosisClinical trialsMonitoring of MSMagnetic resonance imagingPositron emission tomographyDisability worseningKey unmetCentral pathologyEarly pathologyTreatment responseNew therapiesOcular imagingUnmet needResonance imagingEmission tomographyDisease pathologyNew therapeuticsPathologyNeuroimaging measuresTrialsLongitudinal studySclerosisClinicWorseningBiomarkersPhase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis
Wiendl H, Airas L, Chitnis T, Williams M, Nakahara J, Bermel R, Loop B, Hayek G, Bhatt A, Hunter B, Zhang Y, Karan R, Willi R, Kieseier B, Montalban X. Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2023, 80: 105315. DOI: 10.1016/j.msard.2023.105315.Peer-Reviewed Original ResearchBruton's tyrosine kinaseDisease activitySerum neurofilament light chain concentrationNeurofilament light chain concentrationOpen-label extensionKey secondary endpointDisability Status ScaleNew oral treatmentRecent disease activityLight chain concentrationsPercentage of participantsCovalent BTK inhibitorImmune regulatory networkRelated neuroinflammationDisability progressionPrimary endpointSecondary endpointsT1 lesionsTyrosine kinaseOral treatmentRelapse rateT2 lesionsMulticenter studyMultiple sclerosisSafety profileRemibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders (P7-3.015)
Williams M, Airas L, Chitnis T, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, Ziehn M, Willi R, Kieseier B, Nikolaev I, Haemmerle S, Zharkov A, Siegel R, Cenni B, Wiendl H, Maurer M, Giménez-Arnau A, Montalban X. Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders (P7-3.015). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000202933.Peer-Reviewed Original ResearchInternational Consensus on Smoldering Disease in Multiple Sclerosis using the Delphi Method (P11-3.013)
Bagnato F, Scalfari A, Oh J, Airas L, Bittner S, Calabrese M, Dominguez J, Granziera C, Greenberg B, Hellwig K, Illes Z, Lycke J, Traboulsee A, Popescu V, Giovannoni G. International Consensus on Smoldering Disease in Multiple Sclerosis using the Delphi Method (P11-3.013). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203661.Peer-Reviewed Original Research
2022
The White Matter Rounds Experience: The Importance of a Multidisciplinary International Network to Accelerate the Diagnostic Process for Adult Patients with Rare White Matter Disorders (P1-1.Virtual)
Huang Y, Giacomini P, Massie R, Venkateswaran S, La Piana R, Trudelle A, Fadda G, Sharifian-Dorche M, Boudjani H, Poliquin-Lasnier L, Airas L, Saveriano A, Levesque-Roy M, Ziller M, Miller E, Martinez-Rios C, Davila J, Wilson N, Longbrake E, Antel J, Brais B, Bernard G, Rush C. The White Matter Rounds Experience: The Importance of a Multidisciplinary International Network to Accelerate the Diagnostic Process for Adult Patients with Rare White Matter Disorders (P1-1.Virtual). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1528.Peer-Reviewed Original ResearchPhenotyping Of Multiple Sclerosis Lesions According To Innate Immune Cell Activation Using TSPO-PET (S26.003)
Nylund M, Sucksdorff M, Matilainen M, Polvinen E, Tuisku J, Airas L. Phenotyping Of Multiple Sclerosis Lesions According To Innate Immune Cell Activation Using TSPO-PET (S26.003). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2547.Peer-Reviewed Original ResearchTSPO-PET-measurable Microglial Activation Associates with Serum 3-hydroxykynurenine Levels in Multiple Sclerosis Patients (P14-4.007)
Saraste M, Matilainen M, Sucksdorff M, Rajda C, Galla Z, Vécsei L, Airas L. TSPO-PET-measurable Microglial Activation Associates with Serum 3-hydroxykynurenine Levels in Multiple Sclerosis Patients (P14-4.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2556.Peer-Reviewed Original Research